The GSDMD Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human 769-P renal cell carcinoma line. This product features targeted disruption of the GSDMD gene, establishing a loss-of-function model for investigating gasdermin D-dependent pyroptosis. The polyclonal format provides a heterogeneous knockout pool suitable for robust functional studies without single-cell cloning.
The 769-P host cell line is a well-established model of clear cell renal cell carcinoma (ccRCC), isolated from a primary clear cell adenocarcinoma. These cells are deficient in the tumor suppressor VHL, a hallmark of sporadic ccRCC. Their tumorigenic properties and dysregulated hypoxia-responsive signaling make them an ideal background for studying the interplay between cancer and inflammatory cell death mechanisms.
GSDMD is the executioner of pyroptosis, mediating inflammatory cell death and cytokine release. In response to inflammasome activation, caspase-1 (or caspase-4/5) cleaves GSDMD, generating an N-terminal fragment that oligomerizes and inserts into the plasma membrane via interactions with cardiolipin and phosphoinositides. The resulting pores enable secretion of IL-1?? and IL-18, release of alarmins like HMGB1, and eventual cell lysis facilitated by NINJ1. GSDMD acts downstream of sensors such as NLRP3 and AIM2, serving as a central node in pyroptotic signaling.
In the 769-P ccRCC context, GSDMD knockout cells provide a powerful tool to explore pyroptosis within renal cancer biology. While GSDMD-mediated cell death is implicated in sepsis, inflammatory bowel disease, and autoinflammatory disorders, its role in tumor progression and the immune microenvironment is not fully understood. This model allows researchers to assess how GSDMD loss influences tumor cell survival, inflammatory cytokine profiles, and responses to immune effectors in a VHL-deficient background.
This polyclonal knockout is suitable for diverse applications, including mechanistic dissection of pyroptosis and inflammasome signaling, study of inflammatory cell death in cancer, and high-throughput screening for pyroptosis inhibitors. Typical assays include Western blotting for GSDMD cleavage, LDH release and cell viability assays to measure cytolysis, IL-1?? ELISA, and immunofluorescence microscopy to examine pore formation. For ordering information or technical support, please contact Ascent Research.
